Disease activity of lupus nephritis with different pathological types and risk factors of end-stage renal disease: analysis of 305 cases

Qijun WU; Dongmei ZHANG; Zhifang ZHAI; Zhiqiang SONG

doi:10.16016/j.1000-5404.202007102

您当前的位置：

首页 >

文章列表页 >

Disease activity of lupus nephritis with different pathological types and risk factors of end-stage renal disease: analysis of 305 cases

Clinical Medicine | 更新时间：2026-01-09

- Disease activity of lupus nephritis with different pathological types and risk factors of end-stage renal disease: analysis of 305 cases
- Journal of Third Military Medical University Vol. 43, Issue 23, Pages: 2336-2340(2020)
- 作者机构：
  
  400038 重庆，陆军军医大学(第三军医大学)第一附属医院皮肤科
- 作者简介：
- 基金信息：
  
  the General Program of National Natural Science Foundation of China(81673068);the General Program of National Natural Science Foundation of China(81773316)
- DOI：10.16016/j.1000-5404.202007102
  CLC： R181.32;R446.8;R593.242
- Received：11 July 2020，
  
  Revised：2020-09-30，
  
  Published：15 December 2020
- 稿件说明：
移动端阅览
Qijun WU, Dongmei ZHANG, Zhifang ZHAI, et al. Disease activity of lupus nephritis with different pathological types and risk factors of end-stage renal disease: analysis of 305 cases[J]. Journal of Third Military Medical University, 2020, 43(23): 2336-2340.
DOI：

Qijun WU, Dongmei ZHANG, Zhifang ZHAI, et al. Disease activity of lupus nephritis with different pathological types and risk factors of end-stage renal disease: analysis of 305 cases[J]. Journal of Third Military Medical University, 2020, 43(23): 2336-2340. DOI： 10.16016/j.1000-5404.202007102.

摘要

目的

分析狼疮性肾炎(lupus nephritis，LN)患者不同病理分型与临床疾病活动性和预后的关系，以及终末期肾病(end-stage renal disease

ESRD)的危险因素。

方法

回顾性分析本院2013-2018年经肾活检确诊的305例LN患者，按肾脏病理分为毛细血管内细胞增多性LN(包括LN-Ⅲ/Ⅳ146例、合并膜性病变的LN-Ⅲ/Ⅳ+Ⅴ106例)和非毛细血管内细胞增多性LN(LN-Ⅱ/Ⅴ53例)，比较不同病理分型患者的疾病活动性和预后的差异，通过回归分析探索ESRD的危险因素。

结果

与LN-Ⅱ/Ⅴ相比，LN-Ⅲ/Ⅳ(伴或不伴LN-Ⅴ)患者SLEDAI评分≥10分比例更高(66.3%

45.3%)，且出现浆膜炎、脱发、贫血、血肌酐增高、血尿、ESRD以及抗ds-DNA、AnuA抗体阳性的比例均更高(

0.05)。ESRD整体累积发病率为14.4%，LN-Ⅲ/Ⅳ(伴或不伴LN-Ⅴ)是ESRD的独立危险因素(

值为2.977)，此外，抗dsDNA抗体阳性、血肌酐增高、SLEDAI评分≥10分亦为ESRD的独立危险因素(

值分别为1.722、5.484、2.070)。不同病理类型患者的生存时间分布差异无统计学意义(

0.05)。

结论

LN-Ⅲ/Ⅳ(伴或不伴LN-Ⅴ)型患者表现出更高的疾病活动性，肾脏和肾外损害更重，进展为ESRD的风险更高。

Abstract

Objective

To explore the relationship of lupus nephritis (LN) with different pathological types with disease activity and prognosis

and investigate the risk factors of end-stage renal disease (ESRD).

Methods

A total of 305 pathologically-confirmed LN patients admitted in our hospital from the year of 2013 to 2018 were retrospectively enrolled in this study. According to the results of renal biopsy

they were divided into mesangial hypercellularity LN (including 146 cases of LN-Ⅲ/Ⅳ and 106 cases of LN-Ⅲ/Ⅳ+Ⅴ) and non-mesangial hypercellularity LN (53 cases of LN-Ⅱ/Ⅴ). The disease activity and prognosis of the patients with different pathological types were compared

and the risk factors of ESRD were explored.

Results

There were more patients with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) ≥10 (66.3%

45.3%)

occurrences of serositis

hair loss

anemia

higher serum creatinine

hematuria

and ESRD

and manifestations of anti-dsDNA antibody and anti-AnuA antibody in the LN-Ⅲ/Ⅳ patients (with or without LN-Ⅴ) than the LN-Ⅱ/Ⅴ patients (

0.05). The cumulative incidence of ESRD was 14.4%

and LN-Ⅲ/Ⅳ(with or without LN-Ⅴ)

as well as anti-dsDNA antibody

higher serum creatinine

and SLEDAI ≥10

was identified as independent risk factors for ESRD (

=2.977

1.722

5.484

2.070). But there was no statistical difference in survival time among different pathological types (

0.05).

Conclusion

The LN-Ⅲ/Ⅳ patients (with or without LN-Ⅴ) have higher disease activity

severer impairment both in inside and outside of the kidney

and higher risk of progression to ESRD.

关键词

Keywords

references

HANLY J G, O'KEEFFE A G, SU L, et al . The frequency and outcome of lupus nephritis: results from an international inception cohort study[J ] . Rheumatology (Oxford), 2016, 55(2): 252-262. DOI:10.1093/rheumatology/kev311.

[FARINHA F, PEPPER R J, OLIVEIRA D G, et al . Outcomes of membranous and proliferative lupus nephritis: analysis of a single-centre cohort with more than 30 years of follow-up[J ] . Rheumatology (Oxford), 2020.[Epub ahead of print ] . DOI: 10.1093/rheumatology/keaa103 http://dx.doi.org/10.1093/rheumatology/keaa103 ..

YANG J, LIANG D, ZHANG H, et al . Long-term renal outcomes in a cohort of 1814 Chinese patients with biopsy-proven lupus nephritis[J ] . Lupus, 2015, 24(14): 1468-1478. DOI:10.1177/ 0961203315593166.

YAP D Y H, TANG C S O, MA M K M, et al . Survival analysis and causes ofmortality in patients with lupus nephritis[J ] . Nephrol Dial Transplant, 2012, 27(8): 3248-3254. DOI:10.1093/ ndt/gfs073.

ILORI T O, ENOFE N, OOMMEN A, et al . Comparison of outcomes between individuals with pure and mixed lupus nephritis: a retrospective study[J ] . PLoS ONE, 2016, 11(6): e0157485. DOI:10.1371/journal.pone.0157485.

AYODELE O E, OKPECHI I G, SWANEPOEL C R. Long-term renal outcome and complications in South Africans with proliferative lupus nephritis[J]. Int Urol Nephrol, 2013, 45(5): 1289-1300. DOI:10.1007/s11255-012-0376-9.

HOCHBERG M C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40(9): 1725. DOI:10.1002/ art.1780400928.

BAJEMA I M, WILHELMUS S, ALPERS C E, et al . Revision of t he International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices[J ] . Kidney Int, 2018, 93(4): 789-796. DOI:10.1016/j. kint.2017.11.023.

YUAN F, WEI F, HUANG H, et al . The predictive value of autoantibody spectrum on organ damage in patients with systemic lupus erythematosus[J ] . Arch Rheumatol, 2019, 34(2): 157-165. DOI:10.5606/archrheumatol.2019.6981.

AUSTIN H A, ILLEI G G, BRAUN M J, et al . Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy[J ] . J Am Soc Nephrol, 2009, 20(4): 901-911. DOI:10.1681/asn. 2008060665.

YANG J F, XU Z Z, SUI M S, et al . Co-positivity for anti-dsDNA, -nucleosome and -histone antibodies in lupus nephritis is indicative of high serum levels and severe nephropathy[J ] . PLoS ONE, 2015, 10(10): e0140441. DOI:10.1371/ journal.pone.0140441.

胡伟新, 刘春蓓, 孙海鸥, 等. 1352例狼疮性肾炎的临床与免疫学特征[J].肾脏病与透析肾移植杂志, 2006, 15(5): 401-408, 442. DOI:10.3969/j.issn.1006-298X.2006.05.002.

HU W X, LIU C B, SUN H O, et al . Clinical and immunological features of 1352 Chinese patients with lupus nephritis[J ] . Chin J Nephrol Dial Transplant, 2006, 15(5): 401-408, 442. DOI:10.3969/j.issn.1006-298X.2006.05.002.

LI W G, YE Z Z, YIN Z H, et al . Clinical and immunological characteristics in 552 systemic lupus erythematosus patients in a southern province of China[J ] . Int J Rheum Dis, 2017, 20(1): 68-75. DOI:10.1111/1756-185x.12480.

RAHBAR M, CHITSAZIAN Z, ABDOLI F, et al . Pure red cell aplasia due to antibody against erythropoietin in hemodialysis patients[J ] . J Nephropathol, 2017, 6(1): 25-29. DOI:10.15171/ jnp.2017.05.

LEVINE A B, ERKAN D. Clinical assessment and management of cytopenias in lupus patients[J]. Curr Rheumatol Rep, 2011, 13(4): 291-299. DOI:10.1007/s11926-011-0179-5.

ALMAANI S, MEARA A, ROVIN B H. Update on lupus nephritis[J]. Clin J Am Soc Nephrol, 2017, 12(5):825-835. DOI: 10.2215/CJN. 05780616.

AHN S S, YOO J, JUNG S M, et al . Comparison of clinical features and outcomes between patients with early and delayed lupus nephritis[J ] . BMC Nephrol, 2020, 21(1): 258. DOI:10.1186/s12882- 020-01915-5.

TSELIOS K, GLADMAN D D, SU J, et al . Advanced chronic kidney disease in lupus nephritis: is dialysis inevitable?[J ] . J Rheumatol, 2020, 47(9): 1366-1373. DOI:10.3899/jrheum. 191064.

TANG Y, ZHANG X, JI L, et al . Clinicopathological and outcome analysis of adult lupus nephritis patients in China[J ] . Int Urol Nephrol, 2015, 47(3): 513-520. DOI:10.1007/ s11255-014-0903-y.

LERANG K, GILBOE I M, STEINAR THELLE D, et al . Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study[J ] . Lupus, 2014, 23(14): 1546-1552. DOI:10.1177/ 0961203314551083.

WU X Y, YANG M, XIE Y S, et al . Causes of death in hospitalized patients with systemic lupus erythematosus: a 10-year multicenter nationwide Chinese cohort[J ] . Clin Rheumatol, 2019, 38(1): 107-115. DOI:10.1007/s10067-018-4259-z.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy of shared decision-making for dialysis treatment decisions in patients with end-stage renal disease

Clinical analysis of peripheral blood NLR and NHR in carotid atherosclerosis in patients with end-stage renal disease

Risk factors and treatment strategies of digestive tract foreign body perforation

Changes of pituitary hormones and related factors in patients with prolonged disorders of consciousness

Predictive factors for progression to metastatic castration-resistant prostate cancer

Related Author

Fangjian DUAN

Yu SHI

Qin XIE

Lei LEI

Jianping ZHANG

Chunmei LUO

Kun YANG

Qinyun LI

Related Institution

Department of Nephrology, First Affiliated Hospital, Army Medical University(Third Military Medical University)

School of Nursing, First Affiliated Hospital, Army Medical University(Third Military Medical University)

Department of Nephrology, Second Affiliated Hospital, Army Medical University (Third Military Medical University)

Department of Orthopedics, Second Affiliated Hospital, Army Medical University (Third Military Medical University)

Department of Nephrology, Affiliated Hospital of North Sichuan Medical College, Nanchong

⁰